The deal bolsters Bayer through the addition of an AAV manufacturing platform, clinical-stage candidates, and a CDMO unit.

Dan Stanton, Managing editor

October 26, 2020

2 Min Read
Bayer adds AAV-based gene therapy tech in $2bn AskBio buy
Image: iStock/Andrei Stanescu

The deal – which could be worth up to $4 billion – bolsters Bayer’s gene therapy ambitions through the addition of an AAV manufacturing platform, clinical-stage candidates, and a CDMO unit.

German pharma giant Bayer is paying $2 billion up front with potential milestone payments up to another $2 billion for Research Triangle Park, North Carolina-based Asklepios BioPharmaceutical (AskBio).

Founded in 2001 by Jude Samulski, the company’s present chief scientific officer, AskBio is developing gene therapies for neuromuscular diseases, central nervous system disorders, and cardiovascular conditions. It has a candidate for Pompe disease and Congestive heart failure in the clinic, along with a candidate for Parkinson’s disease being developed with Brain Neurotherapy Bio.


Image: iStock/Andrei Stanescu

The therapies are based on the firm’s AAV capsid and promoter library along with a manufacturing platform called Pro10. The technology uses a human embryonic kidney (HEK)-based cell line in serum-free suspension media to develop and produce AAV vectors at high scales and yields. The firm also owns synthetic promoter technology, along with bioinformatics and intelligent data-driven design, from Edinburgh, UK-based firm Synpromics acquired last year.

Meanwhile, the products are made by Viralgen, a San Sebastián, Spain-based contract development and manufacturing organization (CDMO) set up in 2017 as a joint venture between AskBio and Columbus Venture Partners. Under terms of the deal, Bayer will take over the 50% share of the CDMO business from AskBio.

“Our innovation in capsid re-engineering and promoter design, coupled with our scaled manufacturing processes, gives us the tools to provide gene therapy solutions to more people suffering from a wider spectrum of disease that is not being adequately treated today,” said Samulski.

The news comes a year after Bayer bought allogeneic cell therapy developer BlueRock Therapeutics for $240 million.

“With this acquisition, Bayer significantly advances the establishment of a cell and gene therapy platform that can be at the forefront of breakthrough science, contributing to preventing or even curing diseases caused by gene defects and further driving company growth in the future,” said Bayer CEO Werner Baumann.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like